| Literature DB >> 33193642 |
Dan Jiang1,2, Xiaoliang Xie1,3, Zhenhui Lu1,4, Liyuan Liu1, Yuliang Qu1, Shan Wu1, Yanning Li1, Guangqi Li1, Hongxia Wang1, Guangxian Xu1,2.
Abstract
Colorectal cancer (CRC) is one of the most malignant cancers with high morbidity and mortality. MicroRNAs (miRNAs) are small non-coding RNAs that affect biological processes by binding to mRNAs and regulating their expression, and epigenetic alterations including miRNA dysregulation are significantly involved in CRC development. Determining the effect of the miRNA-mRNA network on CRC could be helpful for developing novel therapeutic targets and prognostic biomarkers, and even improving survival. In this study, microarray assays were used to screen differentially expressed miRNAs (DE miRNAs) and mRNAs (DE mRNAs) in CRC and the adjacent normal tissues. Among the detected genes, 42 miRNAs and 142 mRNAs were significantly upregulated in CRC, while 23 miRNAs and 279 mRNAs were significantly downregulated. Through overlapping of predicted targets of DE miRNAs and anti-expressed DE mRNAs, networks of DE miRNAs and DE mRNAs in CRC were established. Additionally, the formation of a protein-protein interaction network of DE mRNAs possibly targeted by DE miRNAs, functional annotation and pathway analysis, stable subnetwork mining, and determination of hub genes provided the probable mechanism used by DE miRNAs and DE mRNAs to regulate CRC growth. Finally, validation of expression and prognostic potential of hub genes provided further support for the results above and indicated that CCL-28, GPR15, PNOC, NUSAP1, and their interacted miRNAs may be a potential signature for prognosis of CRC patients. In sum, we successfully established miRNA-mRNA regulatory networks based on microarray results targeting CRC, and these findings may elucidate the mechanisms used for CRC growth and identify miRNA-related signatures for prognosis and treatment of CRC.Entities:
Keywords: bioinformatic analysis; colorectal cancer; mRNA; microRNA; microarray
Year: 2020 PMID: 33193642 PMCID: PMC7644864 DOI: 10.3389/fgene.2020.560186
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
FIGURE 1Identification of DE miRNAs and mRNAs in CRC. (A) DE miRNAs between CRC cancer and paired adjacent normal tissues; (B) DE mRNAs between CRC cancer and paired adjacent normal tissues. Up: heat maps; Down: volcano plots. Differentially expressed miRNAs and mRNAs were mined through the following criteria: | Fold change| ≥ 2 and P < 0.05.
FIGURE 2Top 10 GO terms for DE mRNAs in CRC. (A) Upregulated DE mRNAs; (B) downregulated DE mRNAs. GO annotation includes analyses in biological process (BP), cellular components (CC), and molecular function (MF).
FIGURE 3KEGG analysis of DE mRNAs in CRC. (A) Top 10 pathways associated with upregulated DE mRNAs; (B) top 10 pathways associated with downregulated DE mRNAs; (C) detailed information on KEGG pathways associated with DE mRNAs in CRC.
FIGURE 4Overlapping of targets of DE miRNAs and anti-expressed DE mRNAs. (A,C) Overlapping and network between targets of upregulated DE miRNAs and downregulated DE mRNAs. (B,D) Overlapping and network between targets of downregulated DE miRNAs and upregulated DE mRNAs.
FIGURE 5PPI networks consisting of DE networks and stable subnetworks. (A,B) PPI and MCODE analysis of upregulated DE mRNAs. (C,D) PPI and MCODE analysis of downregulated DE mRNAs. (A,C) PPI network analyzed by String; (B,D) subnetworks analyzed by MCODE.
Hub genes in the PPI networks in CRC.
| Downregulated candidate genes associated with upregulated miRNAs | P2RY14 SST RAMP1 VIP INSL5 CCL21 PNOC GPR15 GCG GPR27 TAAR5 CCL28 |
| Upregulated candidate genes associated with downregulated miRNAs | CCNA2 NCAPG NUSAP1 HELLS CENPN KIF20B CKAP2 BRCA1 RFC3 ANLN TPX2 TRIP13 |
FIGURE 6GO BP and Reactome pathway analysis targeting genes of subnetworks. (A) Top 10 GO BP of upregulated DE mRNAs; (B) top 10 Reactome pathways of upregulated DE mRNAs; (C) top 10 GO BP of downregulated DE mRNAs; (D) top 10 Reactome pathways of downregulated DE mRNAs.
FIGURE 7Hub gene expression in the TCGA (COAD) database via GEPIA. *P < 0.05.
FIGURE 8The final networks of candidate miRNAs and hub genes. Blue P indicates that the genes and interacted miRNAs have prognostic potential.
The correlation of 22 miRNA-mRNA pairs in COAD.
| hsa-miR-182-3p | GPR15 | 5.95E−08 | –0.25655 |
| hsa-miR-183-5p | PNOC | 3.41E−05 | –0.1975378 |
| hsa-miR-625-5p | CCL21 | 0.000122 | –0.1834191 |
| hsa-miR-512-5p | CCL21 | 0.956847 | –0.0026049 |
| hsa-miR-4728-5p | CCL21 | 0.526583 | –0.0304769 |
| hsa-miR-450b-3p | VIP | 1.61E−06 | –0.2279155 |
| hsa-miR-25-5p | SST | 0.005465 | –0.1331515 |
| hsa-miR-454-5p | P2RY14 | 2.43E−10 | –0.2978361 |
| hsa-miR-490-3p | TPX2 | 0.003476 | –0.1399798 |
| hsa-miR-490-3p | ANLN | 0.115051 | –0.0757548 |
| hsa-miR-193a-5p | TRIP13 | 2.21E−08 | –0.2645125 |
| hsa-miR-193a-5p | RFC3 | 0.000578 | –0.1645506 |
| hsa-miR-2110 | BRCA1 | 0.280792 | –0.0518864 |
| hsa-miR-2110 | CENPN | 0.059785 | –0.0904326 |
| hsa-miR-6730-5p | RFC3 | 0.06376 | –0.0890678 |
| hsa-miR-6730-5p | BRCA1 | 0.060459 | –0.0901959 |
| hsa-miR-6730-5p | CKAP2 | 0.146241 | –0.0698595 |
| hsa-miR-6730-5p | CENPN | 0.002615 | –0.1441285 |
| hsa-miR-6730-5p | HELLS | 0.208851 | –0.0604442 |
| hsa-miR-6730-5p | NUSAP1 | 0.186741 | –0.0634947 |
| hsa-miR-4709-3p | RFC3 | 0.341237 | –0.0457923 |
| hsa-miR-6793-3p | BRCA1 | 0.772704 | –0.0139042 |
| hsa-miR-490-5p | BRCA1 | 0.006446 | –0.1305814 |
Hub genes with prognostic potential and the association between their expression and CRC patient survival.
| NUSAP1 | GSE12945 | Overall survival | Berlin | 218039_at | 62 | 0.042761 | 3.84 [1.04–14.12] | Poorer |
| NUSAP1 | GSE12945 | Disease-free survival | Berlin | 219978_s_at | 51 | 0.01814 | 34.78 [1.83–660.48] | Poorer |
| NUSAP1 | GSE12945 | Overall survival | Berlin | 219978_s_at | 62 | 0.000504 | 34.32 [4.68–251.59] | Poorer |
| CCL28 | GSE17536 | Disease-free survival | MCC | 224240_s_at | 145 | 0.028541 | 0.49 [0.25–0.93] | Better |
| CCL28 | GSE14333 | Disease-free survival | Melbourne | 224027_at | 226 | 0.034875 | 0.82 [0.68–0.99] | Better |
| CCL28 | GSE14333 | Disease-free survival | Melbourne | 224240_s_at | 226 | 0.010374 | 0.66 [0.48–0.91] | Better |
| GPR15 | GSE17537 | Disease-free survival | VMC | 208524_at | 55 | 0.029864 | 0.08 [0.01–0.79] | Better |
| GPR15 | GSE17537 | Disease-specific survival | VMC | 208524_at | 49 | 0.043031 | 0.08 [0.01–0.92] | Better |
| PNOC | GSE17536 | Disease-specific survival | MCC | 205901_at | 177 | 0.02132 | 0.30 [0.11–0.84] | Better |
| PNOC | GSE17536 | Overall survival | MCC | 205901_at | 177 | 0.015574 | 0.34 [0.14–0.82] | Better |